Sign inCreate account

Report workspace

Add to folder
NCT06623279NOT_YET_RECRUITINGanonymous

A Phase 1, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of HG202 High-fidelity CRISPR-Cas13 (hfCas13Y) RNA-targeting Therapy for Neovascular Age-related Macular Degeneration (nAMD)

Sponsor

Source record

HuidaGene Therapeutics Co., Ltd.

Phase

Source record

Phase 1

Modality

AI-normalized

gene therapy

Target

AI-normalized

VEGFA (Vascular Endothelial Growth Factor A) - RNA-targeting via CRISPR/Cas13 technology to inhibit choroidal neovascularization (CNV) in neovascular Age-related Macular Degeneration (nAMD).

Indication / condition

AI-normalized

Neovascular Age-Related Macular Degeneration (nAMD)

Intervention

Source record

HG202

Source & freshness

Source record

NCT ID

NCT06623279

Original source

ClinicalTrials.gov

Source last updated

Oct 02, 2024

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06623279

Title

A Phase 1, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of HG202 High-fidelity CRISPR-Cas13 (hfCas13Y) RNA-targeting Therapy for Neovascular Age-related Macular Degeneration (nAMD)

Sponsor

HuidaGene Therapeutics Co., Ltd.

Status

NOT_YET_RECRUITING

Phase

Phase 1

Condition raw

Neovascular Age-Related Macular Degeneration (nAMD)

Condition normalized

Neovascular Age-Related Macular Degeneration (nAMD)

Modality raw

gene therapy

Modality normalized

gene therapy

Target raw

VEGFA (Vascular Endothelial Growth Factor A) - RNA-targeting via CRISPR/Cas13 technology to inhibit choroidal neovascularization (CNV) in neovascular Age-related Macular Degeneration (nAMD).

Target normalized

VEGFA (Vascular Endothelial Growth Factor A) - RNA-targeting via CRISPR/Cas13 technology to inhibit choroidal neovascularization (CNV) in neovascular Age-related Macular Degeneration (nAMD).

Interventions

HG202

Public preview

Source record

HG202, developed by HuidaGene Therapeutics, represents a novel approach to treating nAMD through a one-time gene-editing therapy that aims to reduce the need for frequent anti-VEGF injections, which are the current standard of care. The potential to provide long-term efficacy with a single administration could significantly alleviate the burden on healthcare systems and improve patient quality of life. The nAMD market is substantial, with existing therapies facing limitations such as treatment resistance and the need for ongoing injections. If successful, HG202 could capture a significant share of this market, particularly among patients who do not respond adequately to current therapies. The trial's outcomes will be critical in determining the asset's commercial viability and positioning against established anti-VEGF therapies.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of HG202 High-fidelity CRISPR-Cas13 (hfCas13Y) RNA-targeting Therapy for Neovascular Age-related Macular Degeneration (nAMD)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT06623279

Status

NOT_YET_RECRUITING

Phase

Phase 1

Sponsor

HuidaGene Therapeutics Co., Ltd.

Executive brief

Investment-Ready Snapshot

HG202, developed by HuidaGene Therapeutics, represents a novel approach to treating nAMD through a one-time gene-editing therapy that aims to reduce the need for frequent anti-VEGF injections, which are the current standard of care. The potential to provide long-term efficacy with a single administration could significantly alleviate the burden on healthcare systems and improve patient quality of life. The nAMD market is substantial, with existing therapies facing limitations such as treatment resistance and the need for ongoing injections. If successful, HG202 could capture a significant share of this market, particularly among patients who do not respond adequately to current therapies. The trial's outcomes will be critical in determining the asset's commercial viability and positioning against established anti-VEGF therapies.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 02, 2024
Internal syncJun 18, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06623279

Indication

Neovascular Age-Related Macular Degeneration (nAMD)

Modality

gene therapy

Target

VEGFA (Vascular Endothelial Growth Factor A) - RNA-targeting via CRISPR/Cas13 technology to inhibit choroidal neovascularization (CNV) in neovascular Age-related Macular Degeneration (nAMD).

Intervention

HG202

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.